Combination

Through the synergistic effects of eperborol and ethambutol, the existing problems of poor treatment effect and drug resistance in NTM infection are solved, providing a more effective treatment plan, significantly improving the effectiveness of treating refractory infections .

CN118984700APending Publication Date: 2024-11-19AN2 THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202280091002.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-10-14
Filing Date
2022-12-06
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The existing treatment methods for non-tuberculous mycobacterium (NTM) infection are not effective, especially the use of multiple antibiotics for a long time, and are prone to drug resistance problems.

Method used

Epetraborole or its hydrate, solvate or salt, combined with ethambutol is used as a method to treat non-tuberculous mycobacterium infection and related diseases, and the therapeutic effect is enhanced through synergistic action.

Benefits of technology

It significantly improves the therapeutic effect on non-tuberculous mycobacterium, reduces the frequency of drug resistance, and provides a more effective treatment for refractory infections.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004979052810000051
    Figure BDA0004979052810000051
  • Figure BDA0004979052810000061
    Figure BDA0004979052810000061
  • Figure BDA0004979052810000131
    Figure BDA0004979052810000131
Patent Text Reader

Abstract

In particular, the present invention relates to the treatment of non-mycobacterium tuberculosis related diseases in humans with eponborole.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] priority

[0002] This application claims the benefit of U.S. Provisional Application Serial Nos. 63 / 286,989, filed on December 7, 2021, and 63 / 416,059, filed on October 14, 2022, both of which are incorporated herein by reference in their entirety. Background of the Invention

[0004] Nontuberculous mycobacterial (NTM) infections are increasing in humans. Standard of care requires treatment with at least three antibiotics for 18-24 months. Despite this, treatment outcomes remain poor.

[0005] New approaches to treat NTM infections would represent an advance in this field. SUMMARY OF THE INVENTION

[0007] In a first aspect, the present invention provides a method for treating nontuberculous mycobacterium infection in a human, comprising: administering epetraborole or a hydrate, solvate or salt thereof and ethambutol to the human, thereby treating the nontuberculous mycobacterium infection in the human.

[0008] In a second aspect, the present invention provides a method for treating a non-tuberculous mycobacterium-related disease in a human, comprising: administering epaborole or a hydrate, solvate or pharmaceutically acceptable salt thereof and ethambutol to the human, thereby treating the non-tuberculous mycobacterium-related disease in the human. DETAILED DESCRIPTION OF THE INVENTION

[0010] I. Definitions and Abbreviations

[0011] In order to more fully understand the present application, several definitions are set forth below. Such definitions are intended to encompass grammatical equivalents.

[0012] The term "about" associated with a reference value may include the value itself and a range of values ​​that are plus or minus 10%. For example, an amount of "about 10" includes 10 and any amount of 9-11. For example, the term "about" associated with a reference value may also include a range of values ​​that are plus or minus 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1% of the value.

[0013] Specific embodiments disclosed herein may be further limited in the claims using "consisting of" or "consisting essentially of" language. When used in a claim, whether filed as an amendment or added, the transitional term "consisting of" excludes any elements, steps, or ingredients not specified in the claim. The transitional term "consisting essentially of" limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristics. The embodiments of the present disclosure so claimed are inherently or expressly described and enabled herein.

[0014] The terms "a," "an," "the" and similar referents used in the context of describing the disclosure (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context.

[0015] As used herein, abbreviations generally have their conventional meanings in the fields of chemistry and biology.

[0016] The following abbreviations are used: AMK-amikacin; ATCC-American Type Culture Collection; CA-MHB-cation-adjusted Mueller Hinton broth; CFU-colony forming unit; CLSI-Clinical and Laboratory Standards Institute; CLR-clarithromycin; EBO-epiborole hydrochloride; EMB-ethambutol; IC-inhibitory concentration; LeuRS-leucyl-tRNA synthetase; MAC-Mycobacterium avium complex; MIC-minimum inhibitory concentration; NTM-nontuberculous mycobacteria; OADC-oleic acid, bovine serum albumin, dextrose, and catalase; RFB-rifabutin; spp.-species; subspp.-subspecies.

[0017] As used herein, "epeborgol of the present invention" refers to epeborgol, salts (eg, pharmaceutically acceptable salts), solvates, and hydrates of these compounds. "Moiety" refers to a group of a molecule that is attached to the rest of the molecule.

[0018] symbol Whether used as a bond or shown perpendicular to a bond, it indicates the point at which the part shown is attached to the rest of the molecule.

[0019] The term "pharmaceutically acceptable salt" includes the ipeborole salts of the present invention, which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When the ipeborole of the present invention contains relatively acidic functional groups, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino (such as choline or diethylamine or amino acids such as d-arginine, l-arginine, d-lysine or l-lysine) or magnesium salts or similar salts. When the ipeborole of the present invention contains relatively basic functional groups, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids such as hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydroiodic or phosphorous acids and the like, as well as salts derived from relatively nontoxic organic acids such as acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-toluenesulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginine salts, and salts of organic acids such as glucuronic acid or galacturonic acid, etc. (see, e.g., Berge et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science 66: 1-19 (1977)). Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base addition salts or acid addition salts.

[0020] The neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner.The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents.

[0021] In addition to salt forms, the present invention provides compounds in prodrug form. Prodrugs of the compounds described herein are susceptible to chemical changes under physiological conditions to provide compounds of the present invention. In addition, prodrugs can be converted into compounds of the present invention in an ex vivo environment by chemical or biochemical methods.

[0022] Some compounds of the present invention may exist in non-solvated forms as well as solvated forms, including hydrated forms. Typically, solvated forms are equivalent to non-solvated forms and are included within the scope of the present invention. Some compounds of the present invention may exist in polymorphic or amorphous forms.

[0023] Certain compounds of the present invention have asymmetric carbon atoms (optical centers) or double bonds; racemates, diastereomers, geometric isomers and individual isomers are included within the scope of the present invention. The illustrations of racemic, ambiscalemic and scalemic or enantiomerically pure compounds used herein are taken from Maehr, J. Chem. Ed. 1985, 62: 114-120. Unless otherwise indicated, solid and broken wedges are used to represent the absolute configuration of stereocenters. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, unless otherwise indicated, the compounds include E and Z geometric isomers. Likewise, all tautomeric forms are included.

[0024] Compounds of the present invention may exist in specific geometric or stereoisomeric forms. The present invention includes all of these compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, racemic mixtures thereof and other mixtures thereof, such as mixtures enriched with enantiomers or diastereomers, all fall within the scope of the present invention. Additional asymmetric carbon atoms may be present in substituents such as alkyl. All of these isomers and mixtures thereof are included in the present invention.

[0025] Optically active (R)- and (S)-isomers, as well as d and l isomers, may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. For example, if a specific enantiomer of a compound of the invention is desired, it may be prepared by asymmetric synthesis or by derivatization with a chiral auxiliary, wherein the resulting diastereomeric mixture is separated and the auxiliary group is cleaved to provide the pure desired enantiomer. Alternatively, when the molecule contains a basic functional group such as an amino group or an acidic functional group such as a carboxyl group, diastereomeric salts may be formed with an appropriate optically active acid or base, and the diastereomers thus formed then resolved by fractional crystallization or chromatographic methods known in the art, followed by recovery of the pure enantiomers. In addition, separation of enantiomers and diastereomers is typically accomplished using chromatography using a chiral stationary phase, optionally in combination with chemical derivatization (e.g., formation of carbamates from amines).

[0026] The compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that make up such compounds. For example, the compounds may be radiolabeled with radioactive isotopes such as tritium ( 3H), iodine-125 ( 125 I) or carbon-14 ( 14 C) All isotopic variations of the compounds of the present invention, whether radioactive or not, are encompassed within the scope of the present invention.

[0027] The term "pharmaceutically acceptable carrier" or "pharmaceutically acceptable vehicle" refers to any formulation or carrier medium that provides for the appropriate delivery of an effective amount of an active agent as defined herein, without interfering with the effectiveness of the biological activity of the active agent, and is sufficiently nontoxic to the host or patient. Representative carriers include water, vegetable and mineral oils, cream bases, lotion bases, ointment bases, and the like. These bases include suspending agents, thickening agents, penetration enhancers, and the like. Their preparation is well known to those skilled in the cosmetic and topical pharmaceutical arts. Additional information on carriers can be found at Remington: The Science and Practice of Pharmacy , 21st ed., Lippincott, Williams & Wilkins (2005), which is incorporated herein by reference.

[0028] The term "excipient" is generally known to refer to a carrier, diluent and / or vehicle used to formulate a pharmaceutical composition effective for the intended use.

[0029] The term "microbial infection" or "infection by microorganisms" refers to any infection of host tissue by an infectious agent, including, but not limited to, bacteria or protozoa (see, e.g., Harrison's Principles of Internal Medicine, pp. 93-98 (Wilson et al., eds., 12th ed. 1991); Williams et al., J. of Medicinal Chem. 42: 1481-1485 (1999), which are incorporated herein by reference in their entirety).

[0030] As used herein, "biological medium" refers to in vitro and in vivo biological environments. Exemplary in vitro "biological medium" includes, but is not limited to, cell culture, tissue culture, homogenate, plasma, and blood. In vivo applications are usually carried out in mammals, preferably humans.

[0031] "Inhibit" and "block" are used interchangeably herein and refer to partial or complete blocking of an enzyme. In an exemplary embodiment, the enzyme is a tRNA synthetase.

[0032] In the present invention, in some cases, boron can form additional covalent bonds or coordinate bonds with oxygen, sulfur or nitrogen.

[0033] Embodiments of the invention also include compounds that are poly- or multi-valent species, including, for example, species such as dimers, trimers, tetramers, and higher homologs of the compounds used in the invention or reactive analogs thereof.

[0034] As used herein, "salt counterion" refers to a positively charged ion that binds to a compound of the invention when boron is fully negatively charged or partially negatively charged. Examples of salt counterions include H + , H 3 O + , ammonium, potassium, calcium, magnesium (as choline or diethylamine or amino acids such as d-arginine, l-arginine, d-lysine or l-lysine) and sodium.

[0035] Compounds comprising boron bonded to carbon and three heteroatoms (e.g., three oxygens as described in this section) may optionally contain fully negatively charged boron or partially negatively charged boron. Due to the negative charge, a positively charged counterion may bind to the compound, thereby forming a salt. Examples of salt counterions include H + , H 3 O + , ammonium, potassium, calcium, magnesium (such as choline or diethylamine or amino acids such as d-arginine, l-arginine, d-lysine or l-lysine) and sodium. Salts of these compounds are implicitly included in the description of these compounds.

[0036] As used herein, a "treatment refractory" infection refers to an infection in which a person's sputum cultures remain positive for nontuberculous mycobacteria after 6 months of treatment with azithromycin (or clarithromycin), rifampin (or rifabutin), and ethambutol.

[0037] II. Introduction

[0038] Ipeborole has been found to be useful in treating certain nontuberculous mycobacterial infections. It has also been found that a combination of Ipeborole and ethambutol is useful in treating certain nontuberculous mycobacterial infections.

[0039] III. Compounds

[0040] Eperborole or its salt, hydrate or solvate

[0041] Iperborole has a structure according to the following formula:

[0042]

[0043] Iperborole can be produced according to methods such as those disclosed in PCT Patent Publication No. WO 2008 / 157726 (PCT Patent Application PCT / US2008 / 07550); U.S. Patent No. 7,816,344 (U.S. Patent Application 12 / 142,692); PCT Patent Publication No. WO 2011 / 127143 (PCT Patent Application PCT / US2011 / 031384); and U.S. Patent No 9,243,003 (U.S. Patent Application 13 / 639,594).

[0044] Iperborole can form hydrates with water, solvates with alcohols such as methanol, ethanol, propanol, etc.; adducts with amino compounds such as ammonia, methylamine, ethylamine, etc.; adducts with acids such as formic acid, acetic acid, etc.; and complexes with ethanolamine, quinoline, amino acids, etc.

[0045] In an exemplary embodiment, the present invention provides ipeborole or a salt, hydrate or solvate thereof, or a combination thereof. In an exemplary embodiment, the present invention provides ipeborole or a salt, hydrate or solvate thereof. In an exemplary embodiment, the present invention provides ipeborole or a salt thereof. In an exemplary embodiment, the salt is a pharmaceutically acceptable salt. In an exemplary embodiment, the present invention provides the hydrochloride salt of ipeborole. In an exemplary embodiment, the present invention provides ipeborole or a hydrate thereof. In an exemplary embodiment, the present invention provides ipeborole or a solvate thereof.

[0046] Standards of care for NTM infections

[0047] According to published recommendations, human NTM infection can be treated with a combination of ethambutol, rifampicin or rifabutin and a macrolide (clarithromycin or azithromycin).

[0048] Ethambutol or its salt, hydrate or solvate

[0049] Ethambutol has a structure according to the following formula:

[0050]

[0051] Ethambutol is produced commercially by a number of manufacturers, such as Sanofi, Cadila, Lupin, and Delmar.

[0052] Rifampicin or its salt, hydrate or solvate

[0053] Rifampin, also known as rifampicin, is produced commercially by a number of manufacturers, such as Novartis, Otto Brandes, Arudavis Labs, and Sichuan Long March Pharma.

[0054] Rifabutin or its salt, hydrate or solvate

[0055] Rifabutin is produced commercially by a number of manufacturers, such as Pfizer, Chongqing HuapontPharma, Lupin, and Guangzhou Tosun Pharma.

[0056] Macrolide (clarithromycin or azithromycin)

[0057] Clarithromycin is produced commercially by a number of manufacturers, such as Sandoz, Century Pharmaceuticals, Teva, Wockhardt, and Alembic.

[0058] Azithromycin is produced commercially by a number of manufacturers, such as Pfizer, Sandoz, Teva, Alembic, and Lupin.

[0059] Synergistic effect with epaborole and ethambutol

[0060] A synergistic effect between epaborole and ethambutol has been discovered that may lead to more effective treatment of NTM infections.

[0061] IV. Methods

[0062] On the other hand, the present invention provides a method for treating a non-tuberculous mycobacterium infection in a person, comprising: administering epaborole or its hydrate, solvate or salt and ethambutol or its hydrate, solvate or salt to a person, thereby treating a non-tuberculous mycobacterium infection in a person. In an exemplary embodiment, the method further comprises administering rifamycin or its hydrate, solvate or salt to a person. In an exemplary embodiment, rifamycin is rifampicin, or its hydrate, solvate or salt. In an exemplary embodiment, rifamycin is rifabutin or its hydrate, solvate or salt. In an exemplary embodiment, rifamycin is rifapentine or its hydrate, solvate or salt. In an exemplary embodiment, rifamycin is rifaximin or its hydrate, solvate or salt. In an exemplary embodiment, the method further comprises administering a macrolide or its hydrate, solvate or salt to a person. In an exemplary embodiment, the macrolide is clarithromycin or its hydrate, solvate or salt. In an exemplary embodiment, the macrolide is azithromycin or a hydrate, solvate or salt thereof. In an exemplary embodiment, epaborole is an epaborole salt, and the salt is a pharmaceutically acceptable salt. In an exemplary embodiment, epaborole is epaborole hydrochloride. In an exemplary embodiment, the nontuberculous mycobacteria are intracellular mycobacteria (M.intracellulare) or avian mycobacterium (M.avium). In an exemplary embodiment, for any method in this paragraph, rifamycin or its hydrate, solvate or salt is not administered to humans. In an exemplary embodiment, for any method in this paragraph, rifabutin or its hydrate, solvate or salt is not administered to humans. In an exemplary embodiment, for any method in this paragraph, macrolide or its hydrate, solvate or salt is not administered to humans. In an exemplary embodiment, for any method in this paragraph, azithromycin or its hydrate, solvate or salt is not administered to humans. In an exemplary embodiment, for any method in this paragraph, clarithromycin or its hydrate, solvate or salt is not administered to humans.

[0063] In another aspect, the present invention provides a method for treating non-tuberculous mycobacterium infection in a human, comprising: administering epaborole or a hydrate, solvate or salt thereof, and ethambutol or a hydrate, solvate or salt thereof, and rifamycin or a hydrate, solvate or salt thereof to a human, thereby treating non-tuberculous mycobacterium infection in a human. In an exemplary embodiment, the non-tuberculous mycobacterium is Mycobacterium intracellulare or Mycobacterium avium.

[0064] In another aspect, the present invention provides a method for treating a non-tuberculous mycobacterium infection in a human, comprising: administering epaborole or a hydrate, solvate or salt thereof, and ethambutol or a hydrate, solvate or salt thereof, and rifabutin or a hydrate, solvate or salt thereof to a human, thereby treating the non-tuberculous mycobacterium infection in the human. In an exemplary embodiment, the non-tuberculous mycobacterium is Mycobacterium intracellulare or Mycobacterium avium.

[0065] In another aspect, the present invention provides a method for treating a nontuberculous mycobacterium infection in a human, comprising: administering epaborole or a hydrate, solvate or salt thereof, and ethambutol or a hydrate, solvate or salt thereof, and a macrolide or a hydrate, solvate or salt thereof to a human, thereby treating the nontuberculous mycobacterium infection in the human. In an exemplary embodiment, the nontuberculous mycobacterium is Mycobacterium intracellulare or Mycobacterium avium.

[0066] In another aspect, the present invention provides a method for treating a non-tuberculous mycobacterium infection in a human, comprising: administering epaborole or a hydrate, solvate or salt thereof, and ethambutol or a hydrate, solvate or salt thereof, and clarithromycin or a hydrate, solvate or salt thereof to a human, thereby treating the non-tuberculous mycobacterium infection in the human. In an exemplary embodiment, the non-tuberculous mycobacterium is Mycobacterium intracellulare or Mycobacterium avium.

[0067] In another aspect, the present invention provides a method for treating a non-tuberculous mycobacterium infection in a human, comprising: administering epaborole or a hydrate, solvate or salt thereof, and ethambutol or a hydrate, solvate or salt thereof, and azithromycin or a hydrate, solvate or salt thereof to a human, thereby treating the non-tuberculous mycobacterium infection in the human. In an exemplary embodiment, the non-tuberculous mycobacterium is Mycobacterium intracellulare or Mycobacterium avium.

[0068] In another aspect, the present invention provides a method for treating nontuberculous mycobacterium infection in a human, comprising: administering epaborole or a hydrate, solvate or salt thereof, and ethambutol or a hydrate, solvate or salt thereof, and rifamycin or a hydrate, solvate or salt thereof, and a macrolide or a hydrate, solvate or salt thereof to a human, thereby treating nontuberculous mycobacterium infection in a human. In an exemplary embodiment, the nontuberculous mycobacterium is Mycobacterium intracellulare or Mycobacterium avium.

[0069] In another aspect, the present invention provides a method for treating a non-tuberculous mycobacterium infection in a human, comprising: administering epaborole or a hydrate, solvate or salt thereof, and ethambutol or a hydrate, solvate or salt thereof, and rifamycin or a hydrate, solvate or salt thereof, and clarithromycin or a hydrate, solvate or salt thereof to a human, thereby treating the non-tuberculous mycobacterium infection in the human. In an exemplary embodiment, the non-tuberculous mycobacterium is Mycobacterium intracellulare or Mycobacterium avium.

[0070] In another aspect, the present invention provides a method for treating a non-tuberculous mycobacterium infection in a human, comprising: administering epaborole or a hydrate, solvate or salt thereof, and ethambutol or a hydrate, solvate or salt thereof, and rifamycin or a hydrate, solvate or salt thereof, and azithromycin or a hydrate, solvate or salt thereof to a human, thereby treating the non-tuberculous mycobacterium infection in the human. In an exemplary embodiment, the non-tuberculous mycobacterium is Mycobacterium intracellulare or Mycobacterium avium.

[0071] In another aspect, the present invention provides a method for treating nontuberculous mycobacterium infection in a human, comprising: administering epaborole or a hydrate, solvate or salt thereof, and ethambutol or a hydrate, solvate or salt thereof, and rifabutin or a hydrate, solvate or salt thereof, and a macrolide or a hydrate, solvate or salt thereof to a human, thereby treating nontuberculous mycobacterium infection in a human. In an exemplary embodiment, the nontuberculous mycobacterium is Mycobacterium intracellulare or Mycobacterium avium.

[0072] In another aspect, the present invention provides a method for treating a non-tuberculous mycobacterium infection in a human, comprising: administering epaborole or a hydrate, solvate or salt thereof, and ethambutol or a hydrate, solvate or salt thereof, and rifabutin or a hydrate, solvate or salt thereof, and clarithromycin or a hydrate, solvate or salt thereof to a human, thereby treating the non-tuberculous mycobacterium infection in the human. In an exemplary embodiment, the non-tuberculous mycobacterium is Mycobacterium intracellulare or Mycobacterium avium.

[0073] In another aspect, the present invention provides a method for treating a non-tuberculous mycobacterium infection in a human, comprising: administering epaborole or a hydrate, solvate or salt thereof, and ethambutol or a hydrate, solvate or salt thereof, and rifabutin or a hydrate, solvate or salt thereof, and azithromycin or a hydrate, solvate or salt thereof to a human, thereby treating the non-tuberculous mycobacterium infection in the human. In an exemplary embodiment, the non-tuberculous mycobacterium is Mycobacterium intracellulare or Mycobacterium avium.

[0074] In an exemplary embodiment, the present invention provides a method for treating a non-tuberculous mycobacterial infection in a human, comprising: administering ipeborole or its hydrate, solvate or salt, and rifamycin or its hydrate, solvate or salt to a human, thereby treating the non-tuberculous mycobacterial infection in the human. In an exemplary embodiment, the present invention provides a method for treating a non-tuberculous mycobacterial infection in a human, comprising: administering ipeborole or its hydrate, solvate or salt, and rifabutin or its hydrate, solvate or salt to a human, thereby treating the non-tuberculous mycobacterial infection in the human. In an exemplary embodiment, the present invention provides a method for treating a non-tuberculous mycobacterial infection in a human, comprising: administering ipeborole or its hydrate, solvate or salt, and macrolide or its hydrate, solvate or salt to a human, thereby treating the non-tuberculous mycobacterial infection in the human. In an exemplary embodiment, the present invention provides a method for treating a non-tuberculous mycobacterial infection in a human, comprising: administering ipeborole or its hydrate, solvate or salt, and clarithromycin or its hydrate, solvate or salt to a human, thereby treating the non-tuberculous mycobacterial infection in the human. In an exemplary embodiment, the present invention provides a method for treating a non-tuberculous mycobacterial infection in a human, comprising: administering to a human ipaborole or a hydrate, solvate or salt thereof, and azithromycin or a hydrate, solvate or salt thereof, thereby treating the non-tuberculous mycobacterial infection in the human. In an exemplary embodiment, the present invention provides a method for treating a non-tuberculous mycobacterial infection in a human, comprising: administering to a human ipaborole or a hydrate, solvate or salt thereof, and rifamycin or a hydrate, solvate or salt thereof, and a macrolide, or a hydrate, solvate or salt thereof, thereby treating the non-tuberculous mycobacterial infection in the human. In an exemplary embodiment, the present invention provides a method for treating a non-tuberculous mycobacterial infection in a human, comprising: administering to a human ipaborole or a hydrate, solvate or salt thereof, and ethambutol or a hydrate, solvate or salt thereof, and rifamycin or a hydrate, solvate or salt thereof, and clarithromycin or a hydrate, solvate or salt thereof, thereby treating the non-tuberculous mycobacterial infection in the human. In an exemplary embodiment, the present invention provides a method for treating a non-tuberculous mycobacterium infection in a human, comprising: administering to a human ipaborole or a hydrate, solvate or salt thereof, and ethambutol or a hydrate, solvate or salt thereof, and rifamycin or a hydrate, solvate or salt thereof, and azithromycin or a hydrate, solvate or salt thereof, thereby treating the non-tuberculous mycobacterium infection in the human. In an exemplary embodiment, the present invention provides a method for treating a non-tuberculous mycobacterium infection in a human, comprising: administering to a human ipaborole or a hydrate, solvate or salt thereof, and rifabutin or a hydrate, solvate or salt thereof, and a macrolide or a hydrate, solvate or salt thereof, thereby treating the non-tuberculous mycobacterium infection in the human.In an exemplary embodiment, the present invention provides a method for treating a non-tuberculous mycobacterium infection in a human, comprising: administering ipaborol or a hydrate, solvate or salt thereof, and clarithromycin or a hydrate, solvate or salt thereof to a human, thereby treating the non-tuberculous mycobacterium infection in the human. In an exemplary embodiment, the present invention provides a method for treating a non-tuberculous mycobacterium infection in a human, comprising: administering ipaborol or a hydrate, solvate or salt thereof, and azithromycin or a hydrate, solvate or salt thereof to a human, thereby treating the non-tuberculous mycobacterium infection in the human. In an exemplary embodiment, the non-tuberculous mycobacterium is Mycobacterium intracellulare or Mycobacterium avium. In an exemplary embodiment, for any method in this paragraph, ethambutol or a hydrate, solvate or salt thereof is not administered to the human.

[0075] In another aspect, the present invention provides a method for treating a nontuberculous mycobacterium infection in a human, comprising: administering epaborole or a hydrate, solvate or salt thereof, and ethambutol or a hydrate, solvate or salt thereof, and a macrolide or a hydrate, solvate or salt thereof to a human, thereby treating the nontuberculous mycobacterium infection in the human. In an exemplary embodiment, the nontuberculous mycobacterium is Mycobacterium intracellulare or Mycobacterium avium.

[0076] In an exemplary embodiment, the nontuberculous mycobacteria grow rapidly. In an exemplary embodiment, the nontuberculous mycobacteria grow rapidly and are Mycobacterium abscessus, Mycobacterium arabiense, Mycobacterium aromaticivorans, Mycobacteremicum, Mycobacterium barrassiae, Mycobacterium bourgelatii, Mycobacterium celeriflavum, Mycobacterium chelonae, Mycobacterium crocinum, Mycobacterium fukienens, Mycobacterium truncatum ... e), M. hippocampi, M. insubricum, M. iranicum, M. litorale, M. llatzerense, M. monacense, M. pallens, M. rufum, M. rutilum, M. salmoniphilum, M. sediminis or Mycobacterium setense, or a combination thereof.

[0077] In an exemplary embodiment, the nontuberculous mycobacterium is slow growing. In an exemplary embodiment, the nontuberculous mycobacterium is slow growing and is Mycobacterium algericum, Mycobacterium alsiense, Mycobacterium aorsiense, Mycobacterium bouchedurhonense, Mycobacterium engbaekii, Mycobacterium europaeum, Mycobacterium fragae, Mycobacterium heraklionense, Mycobacterium intracellularis subspecies (M. indicus pranii), Korean Mycobacterium (M.koreense), Kumamoto Mycobacterium (M.kumamotonense), Xinglin Mycobacterium (M.kyorinense), Tumor-type Mycobacterium lepromatosis (M.lepromatosis), Flemish Mycobacterium (M.liflandii), Lombardy Mycobacterium (M.longobardum), Manten Mycobacterium (M.mantenii), Massa Mycobacterium (M.marseillense), Minnesota Mycobacterium (M.minnesotense), Nijmegen Mycobacterium (M.noviomagense), Paraffin Mycobacterium (M.paraffinicum), Paragordonae Mycobacterium (M.paragordonae), Parakorean Mycobacterium (M.parakoreense) , M. paraseoulense, M. paraterrae, M. riyadhense, M. senuense, M. seoulense, M. sherrisii, M. shigaense, M. shinjukuense, M. simulans, M. sinense, M. stomatepiae, M. timonense, M. vulneris, or M. yongonense, or a combination thereof.

[0078] In an exemplary embodiment, the nontuberculous mycobacterium is selected from the group consisting of Mycobacterium abscessus, Mycobacterium avium complex (MAC), Mycobacterium chelonae, Mycobacterium fortuitum, Mycobacterium gordonae, Mycobacterium kansasii, Mycobacterium mucogenicum, Mycobacterium peregrinum, and Mycobacterium xenopi. In an exemplary embodiment, the nontuberculous mycobacterium is selected from the group consisting of Mycobacterium abscessus, Mycobacterium avium complex (MAC), Mycobacterium fortuitum complex, Mycobacterium gordonae, Mycobacterium kansasii, and Mycobacterium xenopi.

[0079] In an exemplary embodiment, the nontuberculous mycobacterium is the Mycobacterium avium complex. In an exemplary embodiment, the nontuberculous mycobacterium is Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium Marseillaise, Mycobacterium timonei, Mycobacterium estuary du Rhone, Mycobacterium colombiense, Mycobacterium wound or Mycobacterium chimaera. In an exemplary embodiment, the nontuberculous mycobacterium is Mycobacterium intracellulare. In an exemplary embodiment, the nontuberculous mycobacterium is Mycobacterium intracellulare subspecies (M.intracellulare subsp.intracellulare) or Mycobacterium intracellulare subspecies (M.intracellulare subsp.). In an exemplary embodiment, the nontuberculous mycobacterium is Mycobacterium avium.

[0080] In an exemplary embodiment, the human also suffers from a disease, and the disease is cystic fibrosis, chronic obstructive pulmonary disease, or chronic thromboembolic pulmonary hypertension. In an exemplary embodiment, the human also suffers from a disease, and the disease is interstitial lung disease, post-inflammatory pulmonary fibrosis, bronchiectasis, neoplastic disease, diabetes, bronchial asthma, hypothyroidism, mediastinal cysts, or rheumatoid arthritis. In an exemplary embodiment, the human also suffers from a disease, and the disease is interstitial lung disease, and the interstitial lung disease is idiopathic pulmonary fibrosis, sarcoidosis, or proteinosis. In an exemplary embodiment, the human also suffers from a neoplastic disease, and the neoplastic disease is myelofibrosis or lung cancer. In an exemplary embodiment, the human previously suffered from tuberculosis.

[0081] In an exemplary embodiment, the infection is in the lungs of a human. In an exemplary embodiment, the infection is in two or more organs in the body. In an exemplary embodiment, the infection is in a lymph node.

[0082] In an exemplary embodiment, the infection is untreated In an exemplary embodiment, the infection is refractory to treatment.

[0083] On the other hand, the present invention provides a method for treating a non-tuberculous mycobacterium-related disease in a human, comprising: administering ipebobrol or a hydrate, solvate or pharmaceutically acceptable salt thereof and ethambutol to a human, thereby treating a non-tuberculous mycobacterium-related disease in a human. In an exemplary embodiment, the method further comprises administering rifabutin or a salt thereof, or rifamycin or a salt thereof to a human. In an exemplary embodiment, the method further comprises administering a macrolide or a salt thereof to a human. In an exemplary embodiment, the macrolide is clarithromycin or azithromycin. In an exemplary embodiment, ipebobrol is an ipebobrol salt, and the salt is a pharmaceutically acceptable salt. In an exemplary embodiment, ipebobrol is ipebobrol hydrochloride. In an exemplary embodiment, the non-tuberculous mycobacterium-related disease is non-tuberculous mycobacterium lung disease, disseminated non-tuberculous mycobacterium disease or non-tuberculous mycobacterium-associated lymphadenitis. In an exemplary embodiment, the nontuberculous mycobacterium-associated disease is Mycobacterium avium complex (MAC) lung disease, disseminated Mycobacterium avium complex (MAC) disease, and Mycobacterium avium complex (MAC)-associated lymphadenitis. In an exemplary embodiment, the nontuberculous mycobacterium-associated disease is nodular bronchiectasis. In an exemplary embodiment, the nontuberculous mycobacterium-associated disease is fibrocavitary.

[0084] In an exemplary embodiment, the nontuberculous mycobacterium-associated disease is treatment-naive.In an exemplary embodiment, the nontuberculous mycobacterium-associated disease is treatment-refractory.

[0085] In an exemplary embodiment, the disease is treated by oral administration of a compound of the invention. In an exemplary embodiment, the disease is treated by intravenous administration of a compound of the invention. In an exemplary embodiment, the disease is treated by subcutaneous administration of a compound of the invention.

[0086] V. Pharmaceutical Preparations

[0087] In another aspect, the present invention provides a pharmaceutical formulation comprising: a) eperborole or a salt, hydrate or solvate thereof; and b) a pharmaceutically acceptable excipient.

[0088] It is to be understood that the present invention encompasses all combinations of aspects and / or embodiments, as well as suitable, convenient and preferred groups described herein.

[0089] The present invention is further illustrated by the following examples. These examples are not intended to define or limit the scope of the present invention. Example

[0090] Example 1

[0091] Determination of minimum inhibitory concentration (MIC): According to the Clinical and Laboratory Standards Institute document M24-A3 (Clinical and Laboratory Standards Institute. Susceptibility testing of mycobacteria, Nocardia species, and other aerobic actinomycetes. 3rd edition. CLSI Standard M24. Clinical and Laboratory Standards Institute, Wayne, PA: 2018). Agar MIC values ​​were determined essentially as described in CLSI M24-A3 using 7H10 Middlebrook agar and 5% OADC.

[0092] EBO, clarithromycin (CLR), ethambutol (EMB), rifabutin, amikacin, and bedaquiline were tested for in vitro activity against five MAC strains and two fast-growing mycobacterial strains. The MIC results are listed in the table below.

[0093] Table 1. In vitro activity (mg / L)

[0094]

[0095] Example 2

[0096] Combinations of Iperborole

[0097] Iperborole hydrochloride is a small polar molecule with a new mechanism of action (MoA) that has broad-spectrum antibacterial activity, including anti-mycobacterial activity. The current standard of care for Mycobacterium avium complex (MAC) lung disease involves macrolides, ethambutol, and rifamycins. The activity of Iperborole hydrochloride against 7 nontuberculous mycobacteria (including 5 slow-growing nontuberculous mycobacteria and 2 fast-growing mycobacteria) was evaluated in a paired combination with clarithromycin, rifabutin, and ethambutol. The activity of Iperborole hydrochloride was also evaluated in the presence of amikacin and bedaquiline. The results are shown in Table 2 below.

[0098] Materials and methods

[0099] Chemicals

[0100] EBO was obtained from AN2 Therapeutics Inc, bedaquiline was purchased from 1Click Chemistry (KendallPark, NJ), clarithromycin was purchased from Carbosynth (San Diego, CA), and amikacin, ethambutol, and rifabutin were purchased from Sigma-Aldrich, (St.Louis, MO). Frozen stock solutions of the drugs were prepared at 5 mg / ml or 2 mg / ml and frozen in aliquots at -20°C. The stock solutions were thawed and diluted to the appropriate concentrations on the day of the experiment. Middlebrook 7H9 broth and agar, CA-MH agar, and Middlebrook OADC were purchased from Becton-Dickinson and Company (Sparks, MD).

[0101] strain

[0102] Mycobacterium avium 2285R (Verma et al., Microbiol (2019) 10: 693) and Mycobacterium intracellulare DNA000111 were obtained from Diane Ordway (Colorado State University, Fort Collins, CO). Mycobacterium chimera 20-S-05 and macrolide / bedaquiline-resistant Mycobacterium intracellulare 20-S-13 isolates were obtained from Barbara Brown-Elliott (Mycobacteria / Nocardia Research Laboratory, University of Texas Health Science Center, Tyler Tx). Strains Mycobacterium abscessus ATCC 19977, Mycobacterium avium ATCC 700898, and Mycobacterium exogenum ATCC 700686 were obtained from the American Type Culture Collection (ATCC, Manassas, VA). Stock solutions of isolates were prepared and frozen at -80 °C. Fresh cultures (1-2 weeks) of each isolate grown on 7H10 agar plus 5% OADC or CAMH agar plus 5% OADC were used for each experiment.

[0103] Antimicrobial synergy test

[0104] Middlebrook 7H9 + 5% OADC (Dubos et al., Am Rev Tuberc (1947) 56: 334-45) was used as a microbial growth medium, and the chessboard method was used to test synergy and antagonism. The first antibiotic EBO of the combination was diluted continuously along the x-axis, while the second antibiotic was diluted along the y-axis. The sum of the fractional inhibitory concentration (∑FIC) index was used to determine synergistic or antagonistic activity. The FIC index was calculated as the sum of FIC A + FIC B, where FIC A is the MIC of drug A in the combination of drugs A and B divided by the MIC of drug A alone, plus the MIC of drug B in the combination of drugs A and B divided by the MIC of drug B alone. When FIC≤0.5, the combination of drugs is considered synergistic, when FIC>0.5 to 1, the combination of drugs is considered additive, when FIC>1 to 2, the combination of drugs is considered indifferent, and when FIC>2, the combination of drugs is considered antagonistic (EUCAST. Clin. Microbiol. Infect. (2000) 6:503-508).

[0105] Table 2 Summary of the activity of EBO drug combinations

[0106]

[0107] AMK = amikacin, BDQ = bedaquiline, CLR = clarithromycin, EBO = epaborole hydrochloride, EMB = ethambutol, RFB = rifabutin, I = indifferent, A = additive, S = synergistic. NE = no endpoint due to MIC of the second drug out of range, CLR MIC > 128 mg / L, BDQ > 0.5 mg / L.

[0108] Results and discussion

[0109] The in vitro activity of EBO was tested in the presence of clarithromycin, ethambutol, rifabutin, key components of standard of care medications for the treatment of MAC lung disease, and other known active NTM drugs, amikacin and bedaquiline. EBO activity was not antagonized by these drugs for any of the NTM strains we tested. In most cases, particularly for two rapidly growing NTM strains, Mycobacterium abscessus ATCC 19977 and Mycobacterium exogenum ATCC 700686, EBO activity was independent of the addition of a second drug. The only exception was ethambutol, where synergy was observed for 2 strains and additive effects for another 2 strains out of a total of 5 MAC strains tested. Interestingly, the clarithromycin-resistant strain Mycobacterium intracellulare 20-S-13 was the only MAC strain that showed no difference between ethambutol and EBO, and this strain had the highest ethambutol MIC, with a value of 64 mg / L.

[0110] in conclusion

[0111] No antagonism was observed for any strain or EBO combination, and most interactions were largely indiscriminate, especially for two fast-growing NTM strains, M. abscessus ATCC 19977 and M. exogenous ATCC 700686. The only exception was ethambutol, where synergy was observed for 2 strains and additive effects were observed for another 2 strains out of a total of 5 MAC strains tested. Interestingly, the MAC strain with the highest ethambutol MIC value of 64 mg / L was the only strain that showed indifference.

[0112] Example 3

[0113] Determination of the frequency of spontaneous resistance:

[0114] The RF of Mycobacterium avium ATCC 700898 at 2x, 4x and 8x MIC (8 mg / L) EBO was determined, as well as the RF of EBO in combination with CLR, RBT, AMK or EMB. The MICs of the selected EBO mutants to AMK, BDQ, CLR, RBT, EMB and clofazimine (CFZ) were determined, and the mutants were further characterized by genomic DNA analysis. Resistant colonies were confirmed by replicating the plates on agar plates containing the same concentration of antibiotics used to select for resistance. Control plates without drugs were prepared for inoculum determination. RF was calculated by dividing the total CFU / mL of the resistant colonies by the total CFU / mL of the inoculum.

[0115] When selected on 2-8x agar MIC, EBO spontaneous resistance frequencies ranged from 1.58x10 -7 Up to 8.48x10 -9(Table 3). Thus, the EBO resistance frequencies were very similar to those observed with standard of care (SOC) antimicrobial agents (Table 4). However, the addition of EMB, CLR, RFB, or AMK to EBO significantly reduced the resistance frequencies to both drugs by more than 700-fold (Table 4). Further characterization of the EBO resistance mutants showed that the MIC values ​​for EBO increased by 128-fold or more, while the MIC values ​​for amikacin, bedaquiline, clofazimine, clarithromycin, and ethambutol did not change by more than 4-fold (Table 5). The only drug tested that changed more than 4-fold compared to the wild-type MIC value was rifabutin, but this was a single EBO resistance mutant, 64-4A, which changed 8-fold (Table 5). However, this only had a single MIC value because its replicates differed only 4-fold from the wild type. It has been previously reported that this strain of Mycobacterium avium ATCC 700898 has an 8-fold difference from the related rifamycins and rifampicin (Zelinski C, Killian SC, Sulivan N, Allen S. Mycobacterium avium ssp.avium ATCC700898 (QC) culture differences demonstrate variable MIC susceptibility results in the SLOMYCO plate. ASM General Meeting 2010, San Diego CA C-153). This 8-fold difference is within the margin of error. The activity of the key antimicrobial drugs tested was not affected by EBO resistance, indicating that no cross-resistance occurred.

[0116] Table 3. Frequency of in vitro resistance of EBO in Mycobacterium avium ATCC 700898

[0117]

[0118] Table 4. In vitro resistance frequencies of SOC antimicrobials alone and with EBO (2xMIC) in M. avium ATCC 700898

[0119]

[0120]

[0121] Table 5. MIC values ​​(mg / L) of EBO selected isolates of Mycobacterium avium ATCC 700898 compared with the parent strain

[0122]

[0123] It should be understood that the embodiments and implementations described herein are for illustrative purposes only, and that those skilled in the art will propose various modifications or changes based thereon, and that these modifications or changes will be included within the spirit and scope of the present application and within the scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.

Claims

1. A method for treating nontuberculous mycobacterium infection in humans, comprising: Iperborole or a hydrate, solvate or salt thereof and ethambutol are administered to a human to treat a nontuberculous mycobacterium infection in the human.

2. The method according to claim 1, further comprising administering a rifamycin or a salt thereof, or a rifamycin or a salt thereof to a human.

3. The method according to claim 2, wherein the rifamycin is rifampicin (rifampin), rifabutin, rifapentine or rifaximin.

4. The method according to claim 1, 2 or 3, further comprising administering the macrolide or a salt thereof to a human.

5. The method according to claim 4, wherein the macrolide is clarithromycin or azithromycin.

6. The method according to the preceding claim, wherein eperborole is an eperborole salt and the salt is a pharmaceutically acceptable salt.

7. The method according to claim 6, wherein the eperborole is eperborole hydrochloride.

8. A method according to the preceding claim, wherein the nontuberculous mycobacteria grow rapidly.

9. The method according to claim 8, wherein the nontuberculous mycobacterium grows rapidly and is selected from the group consisting of Mycobacterium abscessus, Mycobacterium arabifolium, Mycobacterium dearomatum, Mycobacterium bacteremicum, Mycobacterium parasiticum, Mycobacterium bourgera, Mycobacterium fast-growing yellow, Mycobacterium turtle, Mycobacterium saffron, Mycobacterium franklinii, Mycobacterium fujianensis, Mycobacterium hippocampus, Mycobacterium insubria, Mycobacterium iraniensis, Mycobacterium littoralis, Mycobacterium lat, Mycobacterium muri black, Mycobacterium flavum, Mycobacterium rubrum, Mycobacterium ferruginosa, Mycobacterium salmonophilum, Mycobacterium sedimentum, and Mycobacterium sette.

10. A method according to the preceding claim, wherein the nontuberculous mycobacteria are slow growing.

11. The method according to claim 10, wherein the nontuberculous mycobacterium is slow growing and is selected from the group consisting of Mycobacterium algeriensis, Mycobacterium als, Mycobacterium aarhus, Mycobacterium bouches du Rhône, Mycobacterium ingelbeck, Mycobacterium europaea, Mycobacterium fraga, Mycobacterium heraklion, Mycobacterium intracellulare subsp. intracellulare, Mycobacterium koreana, Mycobacterium kumamoto, Mycobacterium kyorin, Mycobacterium leprae, Mycobacterium flanders, Mycobacterium lombardi, Mycobacterium mandshurica, Mycobacterium truncatum ... Mycobacterium teng, Mycobacterium massa, Mycobacterium minnesota, Mycobacterium niemexiang, Mycobacterium paraffinum, Mycobacterium paragordonum, Mycobacterium parakoreanum, Mycobacterium paraseoulii, Mycobacterium paraterrestris, Mycobacterium riadii, Mycobacterium selaginellae, Mycobacterium selaginellae, Mycobacterium sherry, Mycobacterium shigae, Mycobacterium shinjukue, Mycobacterium simulans, Mycobacterium centrale, Mycobacterium dakoufeiru, Mycobacterium timonei, Mycobacterium wounds, and Mycobacterium lianjiandong.

12. The method according to any one of claims 1 to 7, wherein the nontuberculous mycobacterium is selected from the group consisting of Mycobacterium abscessus, Mycobacterium avium complex (MAC), Mycobacterium chelonae, Mycobacterium fortuitum, Mycobacterium gordonii, Mycobacterium kansasii, Mycobacterium mucogenes, Mycobacterium exogenum and Mycobacterium xenopus.

13. The method according to any one of claims 1 to 7, wherein the nontuberculous mycobacterium is selected from the group consisting of Mycobacterium abscessus, Mycobacterium avium complex (MAC), Mycobacterium fortuitum complex, Mycobacterium gordonii, Mycobacterium kansasii and Mycobacterium xenopi.

14. The method according to any one of claims 1 to 7, wherein the nontuberculous mycobacterium is Mycobacterium avium complex.

15. The method according to any one of claims 1 to 7, wherein the nontuberculous mycobacterium is Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium masseillaris, Mycobacterium timonei, Mycobacterium bouches du Rhône, Mycobacterium columbia, Mycobacterium wounds and Mycobacterium chimaera.

16. The method according to any one of claims 1 to 7, wherein the nontuberculous mycobacterium is Mycobacterium intracellulare.

17. The method according to any one of claims 1 to 7, wherein the nontuberculous mycobacterium is Mycobacterium intracellulare subsp. or Mycobacterium intracellulare subsp. chimaera.

18. The method according to any one of claims 1 to 7, wherein the nontuberculous mycobacterium is Mycobacterium avium.

19. The method according to any one of claims 1 to 7, wherein the nontuberculous mycobacterium is Mycobacterium avium subsp. avium, Mycobacterium avium subsp. hominis, Mycobacterium avium subsp. silvae or Mycobacterium avium subsp. paratuberculosis.

20. The method according to the preceding claim, wherein the human also suffers from a disease which is cystic fibrosis, chronic obstructive pulmonary disease or chronic thromboembolic pulmonary hypertension.

21. The method according to any one of claims 1 to 19, wherein the human also suffers from a disease which is interstitial lung disease, post-inflammatory pulmonary fibrosis, bronchiectasis, a neoplastic disease, diabetes, bronchial asthma, hypothyroidism, mediastinal cysts or rheumatoid arthritis.

22. The method according to claim 21, wherein the interstitial lung disease is idiopathic pulmonary fibrosis, sarcoidosis or proteinosis, and the neoplastic disease is myelofibrosis or lung cancer.

23. A method according to the preceding claim, wherein the human has previously suffered from tuberculosis.

24. The method according to any one of claims 1 to 23, wherein the infection is in the lungs of a human.

25. The method according to any one of claims 1-23, wherein the infection is in two or more organs in the body.

26. The method according to any one of claims 1 to 23, wherein the infection is in the lymph nodes.

27. A method according to the preceding claim, wherein the infection is untreated.

28. A method according to the preceding claim, wherein the infection is refractory to treatment.

29. A method for treating a non-tuberculous mycobacterium-related disease in a human, comprising: Iperborole or a hydrate, solvate or pharmaceutically acceptable salt thereof and ethambutol are administered to a human to treat a non-tuberculous mycobacterium-related disease in the human.

30. The method according to claim 29, further comprising administering to the human rifabutin or a salt thereof, or a rifamycin or a salt thereof.

31. The method according to claim 29 or 30, further comprising administering a macrolide or a salt thereof to a human.

32. The method according to claim 31, wherein the macrolide is clarithromycin or azithromycin.

33. The method according to any one of claims 29-32, wherein eperborole is an eperborole salt and the salt is a pharmaceutically acceptable salt.

34. The method according to claim 33, wherein the eperborole is the hydrochloride salt of eperborole.

35. The method according to any one of claims 29 to 34, wherein the nontuberculous mycobacterium-associated disease is nontuberculous mycobacterium pulmonary disease, disseminated nontuberculous mycobacterium disease or nontuberculous mycobacterium-associated lymphadenitis.

36. The method according to any one of claims 29 to 34, wherein the nontuberculous mycobacterium-associated disease is Mycobacterium avium complex (MAC) lung disease, disseminated Mycobacterium avium complex (MAC) disease and Mycobacterium avium complex (MAC)-associated lymphadenitis.

37. The method according to any one of claims 29 to 34, wherein the nontuberculous mycobacterium-related disease is nodular bronchiectasis.

38. The method according to any one of claims 29 to 34, wherein the nontuberculous mycobacterium-related disease is luminal fibrosis.

39. A method according to the preceding claim, wherein the nontuberculous mycobacterium-related disease is untreated.

40. A method according to the preceding claim, wherein the nontuberculous mycobacterium-associated disease is refractory to treatment.